- Home
- DCI vs LNTH Comparison
DCI vs LNTH Comparison
Compare DCI & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- LNTH
- Stock Information
- Founded
- DCI 1915
- LNTH 1956
- Country
- DCI United States
- LNTH United States
- Employees
- DCI N/A
- LNTH N/A
- Industry
- DCI Pollution Control Equipment
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DCI Industrials
- LNTH Health Care
- Exchange
- DCI Nasdaq
- LNTH Nasdaq
- Market Cap
- DCI 7.9B
- LNTH 7.5B
- IPO Year
- DCI 1987
- LNTH 2015
- Fundamental
- Price
- DCI $69.98
- LNTH $79.78
- Analyst Decision
- DCI Hold
- LNTH Strong Buy
- Analyst Count
- DCI 4
- LNTH 5
- Target Price
- DCI $71.33
- LNTH $133.80
- AVG Volume (30 Days)
- DCI 449.1K
- LNTH 1.4M
- Earning Date
- DCI 06-03-2025
- LNTH 05-07-2025
- Dividend Yield
- DCI 1.54%
- LNTH N/A
- EPS Growth
- DCI 11.79
- LNTH N/A
- EPS
- DCI 3.42
- LNTH 3.53
- Revenue
- DCI $3,633,400,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- DCI $2.95
- LNTH $4.96
- Revenue Next Year
- DCI $3.44
- LNTH $10.25
- P/E Ratio
- DCI $20.40
- LNTH $22.59
- Revenue Growth
- DCI 4.46
- LNTH 12.53
- 52 Week Low
- DCI $57.45
- LNTH $74.34
- 52 Week High
- DCI $78.95
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- DCI 65.21
- LNTH 29.82
- Support Level
- DCI $69.63
- LNTH $77.01
- Resistance Level
- DCI $70.80
- LNTH $83.60
- Average True Range (ATR)
- DCI 0.99
- LNTH 3.74
- MACD
- DCI 0.57
- LNTH -2.67
- Stochastic Oscillator
- DCI 87.48
- LNTH 8.68
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.